

The Tuberculosis Drug Candidate SQ109 and Its Analogs Have Multistage Activity against *Plasmodium falciparum*

Savannah J. Watson, Mariëtte E. van der Watt, Anjo Theron, Janette Reader, Sizwe Tshabalala, Erica Erlank, Lizette L. Koekemoer, Mariska Naude, Marianna Stampolaki, Feyisola Adewole, Katie Sadowska, Pilar Pérez-Lozano, Andreea L. Turcu, Santiago Vázquez, Jihee Ko, Ben Mazurek, Davinder Singh, Satish R. Malwal, Mathew Njoroge, Kelly Chibale, Oluseye K. Onajole, Antonios Kolocouris, Eric Oldfield, and Lyn-Marié Birkholtz*



Cite This: *ACS Infect. Dis.* 2024, 10, 3358–3367



Read Online

ACCESS |




Metrics & More



Article Recommendations



Supporting Information



ABSTRACT: Toward repositioning the antitubercular clinical candidate SQ109 as an antimalarial, analogs were investigated for structure–activity relationships for activity against asexual blood stages of the human malaria parasite *Plasmodium falciparum* pathogenic forms, as well as transmissible, sexual stage gametocytes. We show that equipotent activity (IC₅₀) in the 100–300 nM range could be attained for both asexual and sexual stages, with the activity of most compounds retained against a multidrug-resistant strain. The multistage activity profile relies on high lipophilicity ascribed to the adamantane headgroup, and antiplasmodial activity is critically dependent on the diamine linker. Frontrunner compounds showed conserved activity against genetically diverse southern African clinical isolates. We additionally validated that this series could block transmission to mosquitoes, marking these compounds as novel chemotypes with multistage antiplasmodial activity.

KEYWORDS: *Plasmodium falciparum*, SQ109, antimalarial, transmission-blocking, multistage

Malaria presents an immense challenge to governments and healthcare systems, particularly in tropical regions of the world, with an estimated 247 million cases and 619 000 deaths globally in 2021.¹ The incidence of malaria is spread disproportionately and is primarily accounted for the African region by the World Health Organization (WHO) as a result of the prevalence of *Plasmodium falciparum*, the deadliest of all species, combined with the abundance of the *Anopheles* spp. mosquito vectors. The complexity of the *P. falciparum* (*Pf*) life cycle is underpinned by the various developmental stages within different niches in the human host and mosquito vector.² Elimination of the disease, therefore, requires effective targeting of these multiple stages,^{3,4} including eliminating the asexual replicative stages (asexual blood stages (ABS)) and targeting parasite population bottlenecks that appear at the transition phases of the parasite life cycle to ensure parasite reproduction.⁵ Human-to-mosquito parasite transmission requires mature stage V gametocytes, which are formed by differentiation of gametocytes through five distinct morphological stages, where immature stages (stage I to IV) sequester

in the bone marrow, but stage V gametocytes circulate in the peripheral blood system.⁶ Their developmental timeline and low blood circulation numbers make these stages amenable to pharmacological intervention.⁷ As per the target candidate profiles (TCPs; defined by the Medicines for Malaria Venture, www.mmv.org), compounds with activity against ABS parasites (TCP-1) as well as transmission-blocking ability (TCP-5)² will have the potential to reduce parasite prevalence in endemic areas, clear asymptomatic individuals harboring parasites, and lower the spread of resistance that typically develops against compounds during asexual replication.^{4,6,8}

Received: June 4, 2024

Revised: August 2, 2024

Accepted: August 6, 2024

Published: August 14, 2024






Figure 1. SQ109 is a gametocyte-targeting compound. (A) IC_{50} for parent compound SQ109/1 on asexual parasites (ABS), immature-stage gametocytes (IGc, stage II/III), or late-stage gametocytes (LGc, stage IV/V), under 48 h drug pressure. IC_{50} ABS: $1.58 \pm 0.2 \mu\text{M}$; IC_{50} IGc: $0.38 \pm 0.10 \mu\text{M}$; IC_{50} LGc: $0.14 \pm 0.03 \mu\text{M}$; ** $P < 0.01$ indicates IGc and LGc vs ABS. (B) Chemical structure and summary of the designed structure–activity relationships (SAR-1, SAR-2 and SAR-3) around SQ109/1. Data are from >2 independent biological repeats, mean \pm SE indicated, unpaired Student's t -test applied.




Figure 2. Structures of the compounds investigated. Compounds 1–12 are in SAR-1, 13–18 are in SAR-2, and 19–26 are in SAR-3.













The search for new antimalarial compounds with the ability to target ABS parasites and gametocytes has generally been biased toward compounds targeting the biology important to the asexual stages, with screening campaigns prioritizing hits based on ABS activity and gametocyte activity, adding dual activity value to these.³ An alternative approach previously reported *de novo*, parallel screening against multiple stages, which identified new chemical matter that can target specific life cycle stages of *Pf*.⁴ Interestingly, several compounds were identified with preferential activity against *Pf* late-stage gametocytes (LGc),⁴ providing new chemical starting points for further development and optimization as multistage active compounds. One such compound was the well-characterized antitubercular clinical candidate *N*-geranyl-*N'*-(2-adamantyl)ethane-1,2-diamine, SQ109/1 (Figure 1). This compound displayed >10 -fold selectivity toward LGc *in vitro* ($IC_{50} = 0.14 \mu\text{M}$) compared to ABS ($IC_{50} = 1.58 \mu\text{M}$),⁵ and its transmission-blocking ability was confirmed by its ability to target male gametes with a transmission-reducing activity at 80%.⁴ We show here that this activity extends to immature stage gametocytes (IGc, $IC_{50} = 0.38 \mu\text{M}$ vs LGc $IC_{50} = 0.14 \mu\text{M}$) (Figure 1A).

SQ109/1 is a second-generation ethylenediamine antitubercular that completed phase IIb clinical trials for tuberculosis, and potently targets multidrug-resistant *Mycobacterium tuber-*

culosis (Mtb).^{6,7} Its microbial target was identified as mycobacterial membrane protein large 3 (MmpL3),⁸ involved in cell wall biosynthesis. Additionally, SQ109 was also implicated in the disruption of the proton motive force (PMF)⁹ by acting as an uncoupler, and this has been proposed to be a significant driver of its activity against non-MmpL3 containing organisms, such as *Trypanosoma cruzi* and *Leishmania* spp,^{10,11} where effects on Ca^{2+} homeostasis are also found due to targeting of acidocalcisomes. Given its activity against multiple infectious organisms, a series of SQ109/1 analogs with structural changes centered around the adamantyl C-2 position were evaluated for enhanced activity against mycobacteria and other bacteria and protists, including ABS *Pf*.⁵ We showed that analogs with ethyl, butyl, phenyl and benzyl substituents displayed improved ABS activity over SQ109, with minimal toxicity to human cells, making them of interest as potential multistage antimalarial leads.⁵

These results prompted further investigation of SQ109/1 analogs, including their ability to target multiple parasite stages. Here, we evaluated the structure–activity relationships (SAR) of the SQ109/1 scaffold as multistage active antiplasmodial compounds. SAR exploration involved alkyl and benzyl/phenyl substitution at the C-2 of the adamantyl or replacement of the entire adamantyl group with bioisosteres (SAR-1); methylation, extension, or replacement of the

Table 1. Antiplasmodial Activity of SQ109 Analogs with Changes around the Adamantane

Cpd	X	<i>Pf</i> ABS IC ₅₀ (μM)		<i>Pf</i> NF54 LGc IC ₅₀ (μM)	HepG2 EC ₅₀ (μM) / % viability ^a	WlogP	LogD _{7.4}	Solubility pH 6.5 (μM)	CL _{int} ^b (μL/min/mg; H/R/M)
		NF54	K1 (Dd2)						
1		1.58 ± 0.20 ^c	3.48 ± 0.24 (1.44 ± 0.70)	0.14 ± 0.03	9.21 ± 1.99	4.68	1.87	nd	442/385/410
2		0.16 ± 0.07 ^c	0.10 ± 0.02	0.58 ± 0.04	5.21 ± 1.33	5.46	2.67	840	nd
3		0.27 ± 0.04 ^c	0.13 ± 0.03	0.30 ± 0.03	10.2 ± 1.7	6.24	3.53	nd	nd
4		0.32 ± 0.03 ^c	>5 μM (8.11 ± 0.96)	0.16 ± 0.02	100% ^c	6.3	4.07	13.9	nd
5		0.42 ± 0.09 ^c	5.99 ± 0.63 (5.66 ± 0.31)	0.21 ± 0.02	100% ^c	5.53	4.29	30	400/514/343
6		0.50 ± 0.14	1.33 ± 0.5	0.37 ± 0.02	100% ^c	5.85	3.09	334	322/400/308
7		0.66 ± 0.16 ^c	0.86 ± 0.27	0.20 ± 0.02	100% ^c	5.07	2.26	773	254/373/348
8		0.77 ± 0.10 ^c	1.61 ± 0.55	0.29 ± 0.01	100% ^c	5.85	2.77	2339	426/467/218
9		0.99 ± 0.21	2.32 ± 0.55	0.70 ± 0.01	12.90 ± 1.40	4.83	2.04	nd	nd
10		1.17 ± 0.20	nd	0.5 ± 0.07	97%	4.05	1.41	155	nd
11		1.66 ± 0.3	nd	0.22 ± 0.04	100%	4.44	1.79	nd	nd
12		4.32 ± 0.6	nd	0.41 ± 0.20	94% ^s	3.91	2.45	160	nd

^aHepG2 viability as a % inhibition when treated with compound at 20 μM. ^bMicrosomal stability expressed as apparent intrinsic clearance (CL_{int}) after 30 min incubation with human (H), rat (R) or mouse (M) liver microsomes (μL/min/mg). ^cPublished in Stampolaki *et al.*⁵ All cell growth inhibition data are from ≥2 independent biological repeats, each performed in technical duplicates, mean ± SE indicated. WlogP was predicted using the free web tool, SwissADME²⁰ and log D_{7.4} was computed using Chemicalize (<https://chemicalize.com>). nd = not determined.

ethylenediamine linker (SAR-2) and modifications to the geranyl tail region (SAR-3) (Figure 1B).


RESULTS AND DISCUSSION







We generated several analogs of SQ109/1 (2–26, Figure 2) to explore the activity around SAR-1–3 (Figure 1). The synthesis of most compounds (1–9, 15–21) has been described previously,^{12,13} but compounds 10–14 and 22–26 are new, and their synthesis is provided in the Supporting Information. The identity and purity of all compounds were verified by NMR, with >95% purity (Supporting Information Figures S3 and S4). All compounds were evaluated for their biological activity against ABS parasites of the drug-sensitive NF54 strain of *Pf* (*Pf*NF54 ABS) by detecting SYBR Green I fluorescence as an indicator of parasite proliferation,¹⁴ and compounds with IC₅₀ < 1 μM were further profiled against the multidrug-resistant strain, *Pf*K1, to assess the potential for cross-

resistance. Furthermore, compounds were evaluated against late (stage IV/V) gametocytes from *Pf*NF54 (*Pf*NF54 LGc), with viability detected with PrestoBlue,¹⁵ and orthogonally evaluated for toxicity against a human hepatocellular carcinoma line, HepG2.¹⁶ SQ109/1 and selected analogs were also profiled against circulating clinical isolates of southern African origin to assess whether this series would be clinically and geographically relevant.

Activity in SAR-1. Substitution at the adamantyl C-2 with alkyl or aryl groups led to improvements in ABS activity over compound 1. For example, 2–5 displayed activity <0.5 μM, compound 2 (with the ethyl substitution) being 10-fold more active against ABS parasites than 1, while maintaining activity against late-stage gametocytes (Table 1). These compounds retained their activity against drug-resistant parasites (*Pf*K1) and were not cytotoxic to HepG2 cells (≥50% viability@ 20 μM or IC₅₀ > 25 μM). The compounds' profile shifted to now

Table 2. Antiplasmodial Activity of SQ109 Analogs with Changes around the Ethylenediamine Linker



Cpd	X	<i>Pf</i> ABS IC ₅₀ (μM)		<i>Pf</i> NF54 LGc	HepG2 EC ₅₀	WlogP	LogD _{7.4}
		NF54	K1	IC ₅₀ (μM)	(μM)/ % viability ^a		
13		0.98 ± 0.08	1.05 ± 0.09	0.12 ± 0.03	11.80 ± 0.83	5.07	1.02
14		1.09 ± 0.35	nd	>10	100%	5.03	2.06
15		2.46 ± 0.14	nd	>10	100%	5.11	2.16
16		3.78 ± 0.75	nd	>10	99%	5.11	3.26
17		6.49 ± 0.33 ^b	nd	>10	100% ^b	4.21	3.00
18		>10 ^c	nd	>10	99% ^b	4.21	1.79

^aHepG2 viability as a % inhibition when treated with compound at 20 μM. ^bPublished in Stampolaki et al.⁵ All cell growth inhibition data are from ≥2 independent biological repeats, each performed in technical duplicates, mean ± SE indicated. WlogP was predicted using the free web tool, SwissADME²⁰ and log D_{7.4} was computed using Chemicalize (<https://chemicalize.com>). nd = not determined.

include additional activity against ABS parasites along with LGc activity. This shift is significant and depends on the presence of the adamantyl group. Interestingly, “equipotency” (<2-fold change in IC₅₀) against both ABS parasites and gametocytes could be attained with compounds 3–6. However, replacement of the adamantyl with a phenyl group, as in 12, or substitutions with other heterocycles as in 10 and 11 resulted in a comparative loss of ABS activity (pronounced in 12), while retaining the gametocyte-selective profile observed for 1.

The inclusion of the adamantyl group, therefore, seems to be a driver for the activity of these compounds against ABS parasites and is often used in drug design to provide lipophilicity without impeding solubility, moving a compound to a clinically useful log *P* space.¹⁷ Analysis of the solubility of these analogs showed that alkyl substitutions on the adamantyl somewhat improved solubility, with 2, 6, 7, and 8 more soluble than 1, 4, and 5. The introduction of the adamantyl group might also mean concomitant increased permeation of the blood-brain barrier,¹⁷ as observed for the azidothymidines used to treat HIV.¹⁸ Importantly, evaluation of lipophilicity using the calculated Wlog *P*^{19,20} as well as log D_{7.4} (<https://chemicalize.com>) (Table 1) explained the activity shift of the analogs around SAR-1, with the more lipophilic analogs attaining activity against both ABS parasites and gametocytes, as we observed before for multistage antimalarials (Naude *et al.*, submitted elsewhere). Indeed, lipophilicity was correlated with activity with *Pf*NF54 ABS for both Wlog *P* (Pearson *r* = −0.82, *P* = 0.0011, *n* = 12; Supporting Information Figure S1) and log D_{7.4} (to incorporate computed p*K*_a information

additionally; Pearson *r* = −0.60, *P* = 0.039, *n* = 12; Supporting Information Figure S2). However, less lipophilic compounds 10, 11, and 12 only retain LGc activity, even though parasite-induced uptake mechanisms like the new permeability pathways (NPPs, a *Plasmodium* surface anion-selective channel that allow promiscuous uptake of various solutes), are inactive in mature gametocytes compared to ABS parasites,²¹ and this could support a different mode of action of these compounds in gametocytes. The high lipophilicity (>5) could be of concern regarding these compounds’ metabolic stability and oral bioavailability. However, the sterically bulky group has been shown to modulate intramolecular reactivity and restrict the access of hydrolytic enzymes, increasing drug stability and plasma half-life.¹⁷ We show that metabolic stability in liver microsomes is a concern for these compounds (Table 1), with only minor improvements seen against human microsomes for 7 and 8, compared to 1. The inclusion of the adamantyl group in antimalarials has been seen as critical to compounds such as the ozonide, OZ277 (Arterolane, approved as combination therapy with piperazine; Synriam)²² and its next-generation analogs Artefenomel (OZ439), both of which present potent multistage activity, and where metabolic stability issues have been resolved. Further optimization of SQ109 analogs will need to critically address microsomal stability liabilities.

All the compounds, except for 4 and 5, show comparable activity against the drug-resistant strain *Pf*K1. Interestingly, 4 and 5 are the only aromatic species in SAR-1 (4 contains a benzyl substituent while 5 contains a phenyl group), with 16× and 14× higher IC₅₀s against *Pf*K1. This strain is highly resistant to chloroquine and other antimalarials and is

Table 3. Antiplasmodial Activity of SQ109 Analogs with Changes around the Geranyl Tail

Cpd	X	<i>Pf</i> ABS IC ₅₀ (μM)		<i>Pf</i> NF54 LGc IC ₅₀ (μM)	HepG2 EC ₅₀ (μM)/% viability ^a	WlogP	LogD _{7.4}
		NF54	K1				
19		0.2	0.11 ± 0.01	0.30 ± 0.03	3.50 ± 0.09	4.84	2.23
20		0.39 ± 0.15	0.39 ± 0.01	0.54 ± 0.04	5.11 ± 0.85	6.65	4.29
21		0.65	1.82 ± 0.31	0.51 ± 0.07	75%	6.41	3.53
22		0.73 ± 0.04	1.70 ± 0.21	0.74 ± 0.15	100%	3.23	0.75
23		0.96 ± 0.01	4.14 ± 1.37	1.51 ± 0.42	19.96 ± 5.69	4.83	2.13
24		1.24 ± 0.08	nd	>10	27%	3.96	1.03
25		3.99 ± 0.28	nd	0.11 ± 0.06	91%	3.04	0.61
26		4.28 ± 0.36	nd	0.37 ± 0.06	99%	2.96	0.21

^aHepG2 viability as a % inhibition when treated with compound at 20 μM. All cell growth inhibition data are from ≥2 independent biological repeats, each performed in technical duplicates, mean ± SE indicated. WlogP was predicted using the free web tool, SwissADME²⁰ and log D_{7.4} was computed using Chemicalize (<https://chemicalize.com>). nd = not determined.

associated with increased export of *e.g.*, chloroquine from the digestive vacuole.²³ This phenotype was also replicated in *Pf*Dd2 parasites, also resistant to chloroquine (among other antimalarials), with 4 and 5 losing activity but 1 similarly active (Table 1). These aromatic compounds may therefore be subject to resistance mechanisms similar to those found with chloroquine.

Activity in SAR-2. Changes around the ethylenediamine linker in SAR-2 included an extension of the linker (propylenediamine; 13), methyl substitution of the distal amine (14), and replacing either amine with an electron-withdrawing group (15 and 16, oxygen; 17 and 18, carbonyl). Most of these changes were not tolerated for antiplasmodial activity and resulted in compounds with either similar ABS parasite activity to 1 (~1.6 μM) or worse. This was even more dramatic for activity against late-stage gametocytes, where a 2- to >10-fold loss in activity was evident (Table 2), with gametocytocidal activity critically dependent on the diamine moiety. The loss of activity observed after the replacement of an amine suggests that both basic centers are required for activity against LGc, but not ABS (Table 2). This contrasts with the SAR associated with activity toward *Mtb* where only a single basic center is sufficient to maintain activity.⁹ Interestingly, compared to 1, 13 displayed 1.6-fold improved ABS (*Pf*NF54 ABS IC₅₀ = 0.98 μM vs 1.58 μM for 1) as well as 1.2-fold improved gametocyte activity (*Pf*NF54 LGc IC₅₀ = 0.12 μM vs 0.14 μM), suggesting that extending the length of the linker carbon chain is tolerated, as was seen with a similar

propranolamine⁹ against *Mycobacterium smegmatis* and *Pf*. As with the ethylenediamines, this activity might rely on the conservation of the basic centers and is reminiscent of the effect of other di- and polyamines on the parasite.¹⁴

Activity in SAR-3. For SAR-3, replacing the geranyl tail with different aryl groups (22, 25 and 26) maintained gametocyte activity while improving ABS activity. Extended (21; *Pf*NF54 ABS IC₅₀ = 0.65 μM, *Pf*NF54 LGc IC₅₀ = 0.51 μM) and/or saturated (19; *Pf*NF54 ABS IC₅₀ = 0.20 μM, *Pf*NF54 LGc IC₅₀ = 0.30 μM and 20; *Pf*NF54 ABS IC₅₀ = 0.39 μM, *Pf*NF54 LGc IC₅₀ = 0.54 μM) tails were well tolerated, with these compounds also showing a promising shift to multistage activity. Previously, a similar observation was made for 21, showing 2-fold improvement in activity against *Mtb*, compared to 1. Other unsaturated analogs also maintained activity, however, saturation here led to a loss in antitubercular activity.¹² Shortening the geranyl tail (26) retained gametocyte activity (*Pf*NF54 LGc IC₅₀ = 0.37 μM) but with a loss in ABS activity (*Pf*NF54 ABS IC₅₀ = 4.28 μM). However, the introduction of bulky groups led to a loss in gametocyte activity with a saturated ring not tolerated at all (24, IC₅₀ = >10 μM against LGc), compared to only a 7-fold loss in the phenyl analog 22 (IC₅₀ = 0.74 μM, Table 3). Aromatic groups were tolerated for ABS activity in 22 and 23, but not when the tail length was further reduced as in 25. Compounds 19, 20 and 22 with saturated tails and compound 23 bearing a diphenyl ether moiety were moderately cytotoxic to HepG2 cells. The antiplasmodial activity for these SAR-3

analogs seems driven by lipophilicity, particularly for compounds **20** and **21**. As for SAR-1, ABS activity is lost for more hydrophilic analogs such as **24–26**.

All 25 analogs with ABS $IC_{50} < 10 \mu\text{M}$ showed a good correlation ($r = -0.64$, $P = 0.00051$, Figure S1) between lipophilicity ($W\log P$) and activity, which holds somewhat true for $\log D_{7.4}$ (Figure S2). A search of 633 computed descriptors (<http://www.scbdd.com/chemdes/>) did not improve correlations over those found with $W\log P$. It is of interest that there is no correlation overall between gametocytocidal activity and $W\log P$ ($r = 0.022$, $n = 20$, $P = 0.93$, Figure S1) or with $\log D_{7.4}$ ($r = 0.063$, $n = 20$, $P = 0.79$, Figure S2), with high ligand-lipophilicity efficiency (LLE) obtained with potent gametocytocidal compounds (Figure S3), a relationship that was not as evident for the LLE for ABS activity. This would support different uptake mechanisms in ABS and mature gametocytes as suggested before (Naude *et al.*, submitted elsewhere).²¹ However, the mechanisms of action (uncoupling activity, protein targets, Ca^{2+} homeostasis, *etc.*) could also be very different between these stages and cannot be ignored as explanations for the difference in activity. For example, in earlier work, it was shown that SQ109 targets Ca^{2+} homeostasis in other parasitic protozoa,^{10,11} targeting acidocalcisomes, and the digestive vacuole in malaria parasites has many similarities to these vacuoles,²² including, *e.g.*, a V-type H^+ -ATPase, previously proposed as one target for SQ109 in malaria parasites.⁴ Since the digestive vacuole does not play a major role in gametocytes, this could be one reason for the lack of correlation with lipophilicity, but more work on mechanisms is warranted.

Transmission-blocking Potential of SQ109 and Its Analogs. To validate the transmission-blocking potential of SQ109 and the analogs, compounds with submicromolar activity against LGc were evaluated for their ability to prevent the formation of male and female gametes and oocysts, stages of the parasite that develop within the mosquito vector after gametocyte transmission from humans (Table 4). Most

Table 4. Additional *In Vitro* Life Cycle Stage Profiling of the Most Potent Derivatives

Cpd	male gamete inhibition %	female gamete inhibition %	oocyst formation (% inhibition)	
			TRA ^a	TBA ^b
1	72.98 ± 5.97 ^c	51.74 ± 5.40 ^c	76.0 ± 4.75 ^c	36.0 ± 10.6 ^c
2	95.45 ± 4.55	78.88 ± 4.46	nd	nd
3	81.36 ± 8.64	67.05 ± 0.39	11	36
4	43.94 ± 10.61	74.48 ± 2.26	nd	26
5	48.01 ± 24.82	61.03 ± 14.35	38	63
6	34.59 ± 14.27	64.59 ± 12.33	53	67
7	27.14 ± 14.02	34.05 ± 9.23	nd	nd
8	23.51 ± 9.72	54.00 ± 2.54	nd	nd
9	96.67 ± 3.33	90.50 ± 7.17	70	47
13	90.91 ± 9.09	87.02 ± 3.68	70	64
19	95.45 ± 4.55	86.30 ± 2.58	47	36
20	95.0 ± 5.00	77.52 ± 10.85	75	54
21	95.45 ± 4.55	86.30 ± 2.58	56	20
22	92.12 ± 1.21	85.40 ± 7.62	89	80

^aTransmission-reducing activity (TRA) after a 48 h drug treatment at 2 μM , of a single biological repeat. ^bTransmission-blocking activity (TBA) after a 48 h drug treatment at 2 μM , of a single biological repeat. ^cPublished in Reader *et al.* nd—not determined.

compounds showed comparable or improved activities to those found in **1** against both male and female gametes, but in 9 out of 14 cases, there was more activity against male gametes.

Compounds **19–22**, as well as **9** and **13**, all have activity (~ 70 – 600 nM) against both male and female gametes, with the most potent activity (70 – 200 nM) against the male gametes (Table 4), similar to the majority of antimalarial candidates that also show preferential activity against male gametes.²⁴ However, this sex-specificity is not found for **4–8**, which also have good activity against ABS parasites. This may point to a specific mode of action of these compounds in the parasite's different stages constitutive to ABS parasites and female gametes and does not influence the explosive replication events required for male gamete formation.^{25,26} Gametocidal inhibition did not correlate with lipophilicity. Thus, while there is potent activity against both ABS and sexual forms, the strong lipophilicity correlation is only seen with the ABS forms, particularly with *Pf*NF54.

Transmission-blocking activity was confirmed in the standard membrane feeding assay (SMFA), by determining transmission-reducing activity (TRA; reduction in oocyst counts) and transmission-blocking activity (TBA, reduction in oocyst prevalence), 8–10 days after feeding female mosquitoes on gametocyte-infected blood, treated with selected compounds (at 2 μM). Most compounds reduced the TRA and TBA by >40% (Table 4), with changes in the geranyl tail again correlating with higher TBA and TRA.

The efficacy of **1** and its analogs, **13** and **19**, when evaluated against contemporary African clinical isolates *ex vivo*, was promising (Figure 3), with no significant shift in IC_{50} observed for **1** and only a ~ 2 -fold shift for analogs bearing a saturated tail and extended linker. This suggests potential clinical efficacy toward parasites from a geographically relevant, endemic region. A recent investigation into the link between parasite genetic complexity and differential efficacy of lead antimalarial agents against *Pf* clinical isolates suggests that antimalarials are active against both mono- and multiclinal ABS parasites but that this efficacy decreases toward gametocytes from genetically complex, multiclinal isolates.²⁷ Since SB03/05 are both multiclinal,²⁷ this warrants further investigation into the activity of this series toward clinical gametocytes.

CONCLUSIONS

Here, we designed and synthesized analogs around the core of the antitubercular clinical candidate, SQ109, to achieve multistage antiplasmodial activity. Not only were we able to mimic the gametocytocidal activity of SQ109 previously observed, but we also saw a shift to equipotent dual-activity with marked improvements in ABS activity, suggesting that these compounds can be used both to inhibit ABS parasite proliferation as well as transmission of the sexual stages. This profile depends on the diamine linker, with various substitutions on the adamantane and changes to the geranyl tail tolerated. We postulate that this dual-activity is driven by lipophilicity due to the correlation with $W\log P$ and $\log D_{7.4}$, particularly for ABS activity. This is supported by lipid diffusion as a potential main uptake mechanism, especially in gametocyte stages deficient in facilitated import mechanisms. Although high lipophilicity poses a caveat to this series' metabolic stability and oral bioavailability, there is scope for improving its clinical relevance, as SQ109 has already been in several promising clinical trials for tuberculosis. While the adamantane headgroup affords the necessary lipophilicity and




Figure 3. SQ109 displays *ex vivo* activity on African field isolates. (A) Dose–response analysis of SQ109 on clinical isolates SB03 and SB05 in comparison to lab-adapted NF54 *P. falciparum* parasites. Data are from at least 2 independent biological repeats, mean \pm SE indicated, * $P < 0.05$ is indicated. (B) IC_{50} for SQ109 analogs 13 and 19 against a contemporary African field isolate SB05. IC_{50} of 19 on NF54: 0.2 vs on SB05: 0.95 \pm 0.31 μ M; IC_{50} of 13 on NF54: 0.98 \pm 0.08 μ M vs on SB05: 0.49 \pm 0.09 μ M, * $P < 0.05$ is indicated.

improves plasma half-life, further analogs increasing the polarity around the geranyl tail might be considered, as exemplified by the multistage active ozonide antimalarials. Solubility might be further modulated by minor changes to the linker while maintaining the cationic centers required for dual-activity.

METHODS

Chemistry and ADME Assays. Synthesis and Purity Assessment. All synthetic procedures and characterizations are presented in the [Supporting Information](#).

Solubility in 1% DMSO: 99% PBS Buffer. The stock solutions (10^{-2} M) of the assayed compounds were diluted to decreased molarity, from 300 to 0.1 μ M, in 384 well transparent plate (Greiner 781801) with 1% DMSO:99% PBS buffer. Then, they were incubated at 37 $^{\circ}$ C and the light scattering was measured after 2 h in a NEPHELOstar Plus (BMG LABTECH). The results were adjusted to a segmented regression to obtain the maximum concentration in which compounds are soluble.

Aqueous Solubility. The solubility of each product was evaluated using an HPLC Agilent 1100 with a DAD detector. The samples were injected in an Agilent Poroshell 120 EC-C18, 2.7 μ m, 50 mm \times 4.6 mm column at 40 $^{\circ}$ C and 0.6 mL/min flow. The mobile phase was a mixture of A = water with 0.05% formic acid and B = acetonitrile with 0.05% formic acid. The procedure followed was from 95% A–5% B to 100% B in 3 min, 100% B in 3 min, from 100% B to 95% A–5% B in 1 min, 95% A–5% B in 3 min; the injection volume was set at 75 μ L. To establish the solubility of the different compounds, a saturated solution of each sample in 2–5 mL buffer solution at pH 6.0 was prepared under stirring conditions at 37 $^{\circ}$ C. The samples remained at these conditions between 12–24 h. Then, the samples were filtered through a 0.45 μ m PVDF filter and either directly analyzed or diluted before analyzing. The obtained area under the curve was compared with the one from the standard solution.

Microsomal Stability. The microsomal stability assay used a single-point assay design (Di et al., 2004). Briefly, the compounds were incubated at 1 μ M in human, rat, and mouse liver microsomes (0.4 mg/mL) for 30 min at 37 $^{\circ}$ C. Reactions were quenched by adding ice-cold acetonitrile containing internal standard (carbamazepine, 0.0236 μ g/mL). The samples were then centrifuged, and the samples were analyzed by liquid chromatography with tandem mass

spectrometry (LC-MS/MS) (Agilent Rapid Resolution HPLC, AB SCIEX 4500 MS) for the disappearance of the parent compound. Half-life, clearance and hepatic excretion ratios were determined using standard equations.

Biology: Culture Maintenance and In Vitro Assays.

Ethics Statement. The *in vitro* work described holds ethics approval from the University of Pretoria (Health Sciences (506/2018) and Natural Sciences (180000094) Research Ethics Committee and the University of the Witwatersrand Human Research Ethics Committee (M130569) and Animal Ethics Committee (20190701–70)).

In Vitro Cultivation of Asexual Blood Stages. *P. falciparum* asexual parasites were cultured from drug-sensitive NF54 (*Pf*NF54) and multidrug resistant strains *Pf*K1. Parasites were maintained in human erythrocytes (O+, suspended at 5% hematocrit) in RPMI-1640 culture medium (23.81 mM sodium bicarbonate, 0.024 mg/mL gentamycin, 25 mM HEPES pH 7.5, 0.2% D-glucose, 0.2 mM hypoxanthine and Albumax II) under hypoxic conditions (5% CO₂, 5% O₂ and 90% N₂) with moderate shaking (60 rpm) at 37 $^{\circ}$ C. Cultures were synchronized to >95% in the ring stage with 5% (w/v) D-sorbitol treatment.²⁸

In Vitro Cultivation of Gametocytes. Gametocytogenesis was induced on highly synchronized (>95%) asexual ring-stage parasites from *Pf*NF54 at 0.5% parasitemia and 6% hematocrit and thereafter maintained in glucose-deprived media as previously described.^{29,15} After 3 days, the hematocrit was decreased to 4%. Parasites were maintained in complete culture media supplemented with 50 mM *N*-acetyl-glucosamine 5–10 days post induction to inhibit proliferation of residual asexual blood stages. Gametocyte progression and morphology was also monitored microscopically using Giemsa-stained thin smears.

SYBR Green I Assay. Activity against the asexual stage of *P. falciparum* was evaluated using the SYBR Green I-based fluorescence assay as previously described.^{4,16} Cellular proliferation was measured on synchronized *in vitro* *Pf*NF54 ring-stage parasites (1% parasitemia, 2% hematocrit), following drug pressure for 96 h. Chloroquine was used as the positive drug control for complete inhibition of parasite proliferation.

PrestoBlue Fluorescence Assay. *In vitro* activity against the sexual stages of *P. falciparum* was evaluated using the PrestoBlue fluorescence assay as previously described.⁴ Activity was measured on *Pf*NF54 stage IV/V gametocytes (2% gametocytemia, 5% hematocrit) previously seeded with

compounds (in non-lethal DMSO) for 48 h drug pressure, after which PrestoBlue reagent was added and incubated for 2 h. Fluorescence was detected in the supernatant at 612 nm. Dihydroartemisinin (DHA) was used as a positive drug control.

Male Gamete Exflagellation Inhibition Assay (EIA). The EIA was performed using video microscopy by capturing the movement of exflagellation centers over time as previously described.^{4,30} Mature *PfNF54* stage V gametocytes (>95%) were treated with 2 μ M of drug for 48 h before the activation of exflagellation, without removing drug pressure. Movement was semi-automatically quantified from 15 videos of 8–10 s each between 15 and 22.5 min after incubation. Each video was analyzed using ICY-bio image analysis software.

Female Gamete Inhibition Assay. Similarly, female gametes were activated as described previously.³¹ Monoclonal anti-*Pfs* antibody conjugated to FITC was used to detect female gametes. Image acquisition was performed using a Zeiss Axio Lab.A1 epifluorescence microscope with a 100/1.4 numerical aperture (NA) oil immersion. Thirty images were captured per sample and analyzed manually.

Standard Membrane Feeding Assay (SMFA). SMFA was performed using glass feeders as is outlined.^{4,16} Once again, mature stage V gametocytes (>95%) were treated with 2 μ M of each compound for 48 h prior to feeding. *Anopheles coluzzii* females were allowed to feed on gametocyte cultures (1.5–2.5% gametocytemia, 50% hematocrit in A+ male serum with fresh erythrocytes) in the dark for 40 min. All unfed or partially fed mosquitoes were removed, and remaining females housed for 8–10 days. Mosquitoes were dissected to remove midguts, and oocysts counted under bright field illumination at $\times 20$ – $\times 40$ magnification. The percentage of block in transmission (transmission-blocking activity; TBA) and the percentage of reduction in the number of oocysts (transmission-reducing activity; TRA) were calculated after normalizing to the control untreated sample.

Toxicity Assessment. In Vitro Activity against HepG2 Cells. Human hepatocellular liver carcinoma cells (HepG2) were cultivated *in vitro* in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) heat inactivated fetal bovine serum and 1% (v/v) penicillin/streptomycin.¹⁴ Cells were detached with trypsin treatment at 80% confluency and were seeded in 96-well plates to adhere for 24 h under 5% CO₂, humid (95%) conditions. Cells were subsequently exposed to drug pressure for 24 h and cytotoxicity was then determined using the lactate dehydrogenase (LDH) release assay through the colorimetric detection at 450 nm, as previously outlined.^{4,16}

Data Analysis and In Silico Predictions. Assay reproducibility was evaluated by Z'-factors and data are from a minimum of 3 independent biological repeats as indicated; statistical evaluation was performed with paired, two-tailed *t*-test (GraphPad Prism 8.3.0). The physicochemical properties of the compounds were predicted using either StarDrop version: 7.4.0.35635 (Optibrium Ltd.), the online web server, SwissADME,³² and at <https://chemicalize.com>.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00461>.

Chemical synthesis and characterization; correlations between *Pf*ABS and late-stage gametocyte viability inhibition by SQ109 and its analogs (logIC₅₀, μ M) with W log *P* (Figure S1); correlations between *Pf*ABS and late-stage gametocyte viability inhibition by SQ109 and its analogs (logIC₅₀, μ M) with log *D*_{7,4} (Figure S2); *Pf*ABS and late-stage gametocyte (LGC) activity by SQ109 and its analogs associated to lipophilic ligand efficiency (LLE) (Figure S3). ¹H and ¹³C NMR spectra for final compounds (Figure S4); qNMR spectra (Figure S5); compound SMILES (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Lyn-Marié Birkholtz – Department of Biochemistry, Genetics and Microbiology, University of Pretoria Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0002, South Africa; orcid.org/0000-0001-5888-2905; Email: lynmarie.birkholtz@up.ac.za

Authors

Savannah J. Watson – Department of Biochemistry, Genetics and Microbiology, University of Pretoria Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0002, South Africa

Mariëtte E. van der Watt – School of Health Systems and Public Health (SHSPH), University of Pretoria Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0002, South Africa

Anjo Theron – Next Generation Health, Council for Scientific and Industrial Research, Pretoria 0001, South Africa

Janette Reader – Department of Biochemistry, Genetics and Microbiology, University of Pretoria Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0002, South Africa

Sizwe Tshabalala – Department of Biochemistry, Genetics and Microbiology, University of Pretoria Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0002, South Africa

Erica Erlank – Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Services, Wits Research Institute for Malaria, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Johannesburg 2000, South Africa

Lizette L. Koekemoer – Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Services, Wits Research Institute for Malaria, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Johannesburg 2000, South Africa

Mariska Naude – Department of Biochemistry, Genetics and Microbiology, University of Pretoria Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0002, South Africa

Marianna Stampolaki – Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece

Feyisola Adewole – Department of Biological, Physical and Health Sciences, College of Science, Health & Pharmacy, Roosevelt University, Chicago, Illinois 60605, United States

Katie Sadowska – Department of Biological, Physical and Health Sciences, College of Science, Health & Pharmacy, Roosevelt University, Chicago, Illinois 60605, United States

Pilar Pérez-Lozano – Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona 08028, Spain; orcid.org/0000-0001-6899-066X

Andreea L. Turcu – Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Barcelona E-08028, Spain

Santiago Vázquez – Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Barcelona E-08028, Spain; orcid.org/0000-0002-9296-6026

Jiheo Ko – Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-7970-1509

Ben Mazurek – Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-8555-4963

Davinder Singh – Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States

Satish R. Malwal – Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0001-7606-1932

Mathew Njoroge – Drug Discovery and Development Centre (H3D), University of Cape Town, Capetown 7701, South Africa

Kelly Chibale – Drug Discovery and Development Centre (H3D) and South African Medical Research Council Drug Discovery and Development Centre, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Capetown 7701, South Africa; orcid.org/0000-0002-1327-4727

Oluseye K. Onajole – Department of Biological, Physical and Health Sciences, College of Science, Health & Pharmacy, Roosevelt University, Chicago, Illinois 60605, United States

Antonios Kolocouris – Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece; orcid.org/0000-0001-6110-1903

Eric Oldfield – Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-0996-7352

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsinfecdis.4c00461>

Author Contributions

These authors (S.W. and M. vdW) contributed equally to this work. O.K.O. (with F.A. and K.S.), A.K. (with M.S.) and S.V. (with A.L.T.), S.R.M., D.S.S. and E.O. conducted compound design, synthesis, and characterization. Solubility data was provided by P.P.L., A.L.T. and S.V. *In vitro* antiplasmodium and toxicity evaluation was performed by S.W., M.vdW., A.Th., S.T., M.N. and J.R. and managed by L.M.B. and mosquito infections by J.R., E.E. and L.L.K. Microsomal data was

provided by the Drug Discovery and Development Centre (H3D), University of Cape Town (M.Nj., K.C.). M.N., S.W., S.R.M., J.K., B.M. and E.O. analyzed data. The manuscript was written by S.W., M.vdW., and L.M.B., with help in review from all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Abel Tilahun for his technical contribution in compound synthesis. We gratefully acknowledge the Bill and Melinda Gates Foundation Grand Challenges Africa grant (GCA/DD2/Round10/021/001 to L.M.B.) managed through the Science for Africa Foundation (SFA); the Medicines for Malaria Venture, the South African Medical Research Council (SAMRC to L.M.B. and K.C.) and the South African Research Chairs Initiative (SARChI) of the Department of Science and Innovation (DSI) administered through the South African National Research Foundation (NRF) for their support (L.M.B.—UID 84627 and K.C.); K.C. is the Neville Isdell Chair in African-centric Drug Discovery and Development and thanks Neville Isdell for generously funding the Chair. The Office of Student Research, and Honors Program at Roosevelt University for funding provided to A.T., F.A. & K.S., and a Harriet A. Harlin Professorship and the University of Illinois Foundation to E.O.. We thank Gary L. Turner (Spectral Data Services, Inc.) for providing the qNMR analysis of SQ109 (1). We also thank Anjo Theron (Council for Scientific and Industrial Research) for biological analyses.

ABBREVIATIONS

SMFA: standard membrane feeding assay; TBA: transmission-blocking activity; TCP-1: target candidate profile-1; TCP-5: target candidate profile-5; TRA: transmission-reducing activity

REFERENCES

- (1) World Health Organisation. *WHO World Malaria Report CC BY-NC-SA 3.0*; IGO: Geneva, 2022.
- (2) Burrows, J. N.; Duparc, S.; Gutteridge, W. E.; van Huijsduijnen, R. H.; Kaszubska, W.; Macintyre, F.; Mazzuri, S.; Möhrle, J. J.; Wells, T. N. New developments in anti-malarial target candidate and product profiles. *Malaria J.* **2017**, *16*, No. 26.
- (3) Birkholtz, L.-M.; Alano, P.; Leroy, D. Transmission-blocking drugs for malaria elimination. *Trends Parasitol.* **2022**, *38* (5), 390–403.
- (4) Reader, J.; van der Watt, M. E.; Taylor, D.; Le Manach, C.; Mittal, N.; Otilie, S.; Theron, A.; Moyo, P.; Erlank, E.; Nardini, L.; et al. Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box. *Nat. Commun.* **2021**, *12* (1), No. 269.
- (5) Stampolaki, M.; Malwal, S. R.; Alvarez-Cabrera, N.; Gao, Z.; Moniruzzaman, M.; Babii, S. O.; Naziris, N.; Rey-Cibati, A.; Valladares-Delgado, M.; Turcu, A. L.; et al. Synthesis and testing of analogs of the tuberculosis drug candidate SQ109 against bacteria and protozoa: identification of lead compounds against *Mycobacterium abscessus* and malaria parasites. *ACS Infect. Dis.* **2023**, *9* (2), 342–364.
- (6) Heinrich, N.; Dawson, R.; du Bois, J.; Narunsky, K.; Horwith, G.; Phipps, A. J.; Nacy, C. A.; Aarnoutse, R. E.; Boeree, M. J.; Gillespie, S. H.; et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. *J. Antimicrob. Chemother.* **2015**, *70* (5), 1558–1566.

- (7) Sacksteder, K. A.; Protopopova, M.; Barry, C. E.; Andries, K.; Nacy, C. A. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. *Future Microbiol.* **2012**, *7* (7), 823–837.
- (8) Zhang, B.; Li, J.; Yang, X.; Wu, L.; Zhang, J.; Yang, Y.; Zhao, Y.; Zhang, L.; Yang, X.; Yang, X.; et al. Crystal structures of membrane transporter MmpL3, an anti-TB drug target. *Cell* **2019**, *176* (3), 636–648. e613.
- (9) Li, K.; Schurig-Briccio, L. A.; Feng, X.; Upadhyay, A.; Pujari, V.; Lechartier, B.; Fontes, F. L.; Yang, H.; Rao, G.; Zhu, W.; et al. Multitarget drug discovery for tuberculosis and other infectious diseases. *J. Med. Chem.* **2014**, *57* (7), 3126–3139.
- (10) Veiga-Santos, P.; Li, K.; Lameira, L.; De Carvalho, T. M. U.; Huang, G.; Galizzi, M.; Shang, N.; Li, Q.; Gonzalez-Pacanoska, D.; Hernandez-Rodriguez, V.; et al. SQ109, a new drug lead for Chagas disease. *Antimicrob. Agents Chemother.* **2015**, *59* (4), 1950–1961.
- (11) García-García, V.; Oldfield, E.; Benaim, G. Inhibition of *Leishmania mexicana* growth by the tuberculosis drug SQ109. *Antimicrob. Agents Chemother.* **2016**, *60* (10), 6386–6389.
- (12) Onajole, O. K.; Govender, P.; van Helden, P. D.; Kruger, H. G.; Maguire, G. E.; Wiid, I.; Govender, T. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. *Eur. J. Med. Chem.* **2010**, *45* (5), 2075–2079.
- (13) Onajole, O. K.; Coovadia, Y.; Kruger, H. G.; Maguire, G. E.; Pillay, M.; Govender, T. Novel polycyclic ‘cage’-1, 2-diamines as potential anti-tuberculosis agents. *Eur. J. Med. Chem.* **2012**, *54*, 1–9.
- (14) Verlinden, B. K.; Louw, A.; Birkholtz, L.-M. Resisting resistance: is there a solution for malaria? *Expert Opin. Drug Discovery* **2016**, *11* (4), 395–406.
- (15) Reader, J.; Botha, M.; Theron, A.; Lauterbach, S. B.; Rossouw, C.; Engelbrecht, D.; Wepener, M.; Smit, A.; Leroy, D.; Mancama, D.; et al. Nowhere to hide: interrogating different metabolic parameters of *Plasmodium falciparum* gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. *Malaria J.* **2015**, *14*, No. 213.
- (16) Leshabane, M.; Dziwornu, G. A.; Coertzen, D.; Reader, J.; Moyo, P.; van der Watt, M.; Chisanga, K.; Nsanzubuhoro, C.; Ferger, R.; Erlank, E.; et al. Benzimidazole derivatives are potent against multiple life cycle stages of *Plasmodium falciparum* malaria parasites. *ACS Infect. Dis.* **2021**, *7* (7), 1945–1955.
- (17) Liu, J.; Obando, D.; Liao, V.; Lifa, T.; Codd, R. The many faces of the adamantyl group in drug design. *Eur. J. Med. Chem.* **2011**, *46* (6), 1949–1963.
- (18) Tsuzuki, N.; Hama, T.; Kawada, M.; Hasui, A.; Konishi, R.; Shiwa, S.; Ochi, Y.; Futaki, S.; Kitagawa, K. Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. *J. Pharm. Sci.* **1994**, *83* (4), 481–484.
- (19) Daina, A.; Zoete, V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. *ChemMedChem* **2016**, *11* (11), 1117–1121.
- (20) Daina, A.; Michielin, O.; Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* **2017**, *7* (1), No. 42717.
- (21) Bouyer, G.; Barbieri, D.; Dupuy, F.; Marteau, A.; Sissoko, A.; N’dri, M.-E.; Neveu, G.; Bedault, L.; Khodabux, N.; Roman, D.; et al. *Plasmodium falciparum* sexual parasites regulate infected erythrocyte permeability. *Commun. Biol.* **2020**, *3* (1), No. 726.
- (22) Valecha, N.; Looareesuwan, S.; Martensson, A.; Abdulla, S. M.; Krudsood, S.; Tangpukdee, N.; Mohanty, S.; Mishra, S. K.; Tyagi, P.; Sharma, S.; et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated *Plasmodium falciparum* malaria: a phase II, multicenter, randomized, dose-finding clinical trial. *Clin. Infect. Dis.* **2010**, *51* (6), 684–691.
- (23) Shafik, S. H.; Cobbold, S. A.; Barkat, K.; Richards, S. N.; Lancaster, N. S.; Llinás, M.; Hogg, S. J.; Summers, R. L.; McConville, M. J.; Martin, R. E. The natural function of the malaria parasite’s chloroquine resistance transporter. *Nat. Commun.* **2020**, *11* (1), No. 3922.
- (24) Delves, M. J.; Ruecker, A.; Straschil, U.; Lelièvre, J.; Marques, S.; López-Barragán, M. J.; Herreros, E.; Sinden, R. E. Male and female *Plasmodium falciparum* mature gametocytes show different responses to antimalarial drugs. *Antimicrob. Agents Chemother.* **2013**, *57* (7), 3268–3274.
- (25) van der Watt, M. E.; Reader, J.; Birkholtz, L.-M. Adapt or Die: Targeting Unique Transmission-Stage Biology for Malaria Elimination. *Front. Cell. Infect. Microbiol.* **2022**, *12*, No. 901971.
- (26) Tsebriy, O.; Khomiak, A.; Miguel-Blanco, C.; Sparkes, P. C.; Gioli, M.; Santelli, M.; Whitley, E.; Gamo, F.-J.; Delves, M. J. Machine Learning-based Phenotypic Imaging to Characterise the Targetable Biology of *Plasmodium falciparum* Male Gametocytes for the Development of Transmission-Blocking Antimalarials. *PLoS Pathog.* **2023**, *19*, No. e1011711.
- (27) Greyling, N.; van der Watt, M.; Gwarinda, H.; van Heerden, A.; Greenhouse, B.; Leroy, D.; Niemand, J.; Birkholtz, L. M. Genetic complexity alters drug susceptibility of asexual and gametocyte stages of *Plasmodium falciparum* to antimalarial candidates. *Antimicrob. Agents Chemother.* **2024**, *68* (3), No. e0129123.
- (28) Smilkstein, M.; Sriwilajaroen, N.; Kelly, J. X.; Wilairat, P.; Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. *Antimicrob. Agents Chemother.* **2004**, *48* (5), 1803–1806.
- (29) Reader, J.; Opperman, D. F.; van der Watt, M. E.; Theron, A.; Leshabane, M.; da Rocha, S.; Turner, J.; Garrabrant, K.; Piña, I.; Mills, C.; et al. New Transmission-Selective Antimalarial Agents through Hit-to-Lead Optimization of 2-([1, 1'-Biphenyl]-4-carboxamido) benzoic Acid Derivatives. *ChemBioChem* **2022**, *23* (21), No. e202200427.
- (30) Coetzee, N.; von Grüning, H.; Opperman, D.; van der Watt, M.; Reader, J.; Birkholtz, L.-M. Epigenetic inhibitors target multiple stages of *Plasmodium falciparum* parasites. *Sci. Rep.* **2020**, *10* (1), No. 2355.
- (31) Arendse, L. B.; Murithi, J. M.; Qahash, T.; Pasaje, C. F. A.; Godoy, L. C.; Dey, S.; Gibbard, L.; Ghidelli-Disse, S.; Drewes, G.; Bantscheff, M.; et al. The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple *Plasmodium* kinases and life cycle stages. *Sci. Transl. Med.* **2022**, *14* (667), No. eabo7219.
- (32) Daina, A.; Michielin, O.; Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* **2017**, *7*, No. 42717.